Difference between revisions of "2012 Group 5 Project"

From CellBiology
Line 346: Line 346:
# A “recombinant adenovirus (Ad-CBR) that constitutively expresses the β-catenin binding domain of APC” <ref name="PMID15578921"><pubmed>15578921</pubmed></ref> was developed, enabling APC to maintain its function of β-catenin degradation.
# A “recombinant adenovirus (Ad-CBR) that constitutively expresses the β-catenin binding domain of APC” <ref name="PMID15578921"><pubmed>15578921</pubmed></ref> was developed, enabling APC to maintain its function of β-catenin degradation.
# Monoclonal antibodies are being used against Wnt proteins by inducing apoptosis in cancer cells <ref name="PMID15578921"/>.
# Monoclonal antibodies are being used against Wnt proteins by inducing apoptosis in cancer cells <ref name="PMID15578921"/>.
===Other Areas of Current Research===
===Other Areas of Current Research===

Revision as of 15:44, 24 May 2012

2012 Projects: Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Group 6 | Group 7 | Group 8 | Group 9
Figure 1. 30 Years of Wnt Signalling Conference

Wnt/β-catenin Signalling Pathway

2012 marks the 30th anniversary of the identification of Wnt-1, the first component of the Wnt signaling pathway to be discovered. Since this breakthrough, researchers from around the globe have extensively studied and pieced together the multiple components that form the Wnt signaling pathway as it is known and accepted today.


The classical pathway of Wnt signalling that is best understood in current research is the Wnt/β-catenin signalling pathway. This signal transduction pathway is evolutionarily conserved and features heavily in development, regeneration, stem cell regulation and cellular processes such as proliferation and migration[1].

The term 'Wnt' was coined to reflect the homolog genes: Wingless in Drosophila and Int-1 in mammals. Wnt proteins encompass a network of secreted glycolipoproteins[1], forming the basis of this highly conserved pathway. The various elements, agonists and antagonists of this pathway will be discussed, with key emphasis on the structure and function.

Furthermore, mutations in components of this pathway have been associated with cancers, developmental defects and other diseases which will be discussed in further detail.

It is important to note that the Wnt/β-catenin signalling pathway is becoming increasingly complex with the addition of new molecules being discovered in recent years. Areas of current research and future directions will also be outlined.


1973: A mutant of Drosophila melanogaster which had no wings was characterised as Wingless (Wg) [2]

1982: Roel Nusse and Harold Varmus found that mouse mammary tumour virus (MMTV) stimulated tumour formation when the Int1 (integration 1) gene was activated.[3]

1987: Rijsewijk et al identifies the mammalian homolog of the Drosophila Wingless gene as Int1.[4]

1989: Screening of zygotic lethal mutations in Drosophila identified new Wnt signalling molecules e.g. Dishevelled and Shaggy.[5]

1990: Riggleman et al reports on how the accumulation of Armadillo (mammalian homolog is beta-catenin) in Drosophila is posttranscriptionally controlled by the Wingless gene.[6]

1991: The nomenclature of Wingless and Int-1 was combined to form the mnemonic, Wnt.[7]

1991: Molecular cloning of β-catenin[8], LEF (lymphoid enhancer factor)[6] and TCF (T-cell factor)[9] transcription factors was conducted.

1992: Wingless signaling was discovered to be regulated by zeste-white 3 (also called Shaggy), which is the Drosophila homolog of mammalian Glycogen Synthase Kinase-3 (GSK-3).[10]

1993: Through nucleotide sequence analysis and peptide mapping, APC was found to associated with β-catenin[11][12]

1994: Mutations in Dishevelled affected phenotype and gene expression, indicating its crucial role in the Wnt signalling pathway[13]

1995: APC is involved in the degradation of β-catenin and hence regulates its cytoplasmic levels[14]

1996: The interaction of β-catenin with the transcription factors LEF and TCF was discovered[15]

1996: Bhanot et al identifies Frizzled as a receptor for Wnt ligands[16]

Figure 2. Overall structure of the β-catenin/XAxin-CBD complex

1996: A transmembrane protein identified as Porcupine was found to be involved in the processing of Wnt ligands[17]

1996: β-catenin levels were reported to be three times higher in tumour tissues than in normal specimens, indicating the link between β-catenin accumulation and colorectal cancers[18]

1997: Huber et al investigates the three dimensional structure of β-catenin[19]

1997: Phosphorylation of β-catenin by GSK3β (in the absence of Wnt) signals degradation via ubiquitin/proteasome[20]

1997: The gene expression of the homeotic gene Ubx is discovered to be controlled by Wnt signalling, thus implicating Ubx as the first Wnt target gene[21]

1998: Axin 1 and axin 2 were found to be important components of the ‘destruction complex’ (GSK3β and APC) and promoted the phosphorylation of β –catenin[22][23]

1999: Peters et al identifies the function of Casein kinase 1 (CK1) in increasing the phosphorylation of ’’’LRP’’’, boosting its ability to recruit Axin[24]

1999: Protein phosphatase (PP2A) is involved in the regulation of GSK3β-dependent phosphorylation of β–catenin[25][26]

2000: Graham et al determines the 3D crystal structure of the β-catenin–TCF complex[27]

2000: Low-density lipoprotein receptor-related proteins (LRP) such as ’’’LRP’’’5 and ’’’LRP’’’6 interact with Wnt proteins and function as coreceptors of the Frizzled receptor[28]

2001: Wnt protein interacts with ’’’LRP’’’5 and enhances the binding of axin to the intracellular domain of ’’’LRP’’’5[29]

2003: An alternate Wnt receptor, besides Frizzled, was recognised as Derailed in Drosophila (RYK in mammals)[30]

2003: Xing et al determines the crystal structure of the β-catenin/Axin complex (Figure 2) and investigates the structural interactions between them[31]

2006: Caveolin is involved in internalising the ’’’LRP’’’6 receptor and inhibits the binding of β-catenin to Axin[32]

2007: Dishevelled polymerises when recruited to the plasma membrane, allowing it to act as a scaffold for other interactions[33]

2008: Using an siRNA screen, Major et al identified AGGF1 as a chromatin associated protein that involved in regulating β-catenin mediated transcription[34]

2010: A mediator of Hippo signalling known as TAZ inhibits Wnt signalling by binding to Dishevelled[35]

Key players in Wnt/β-catenin signalling

Protein (Gene) Diagram Structure Function Inhibitors
Wnt (WNT) 250px Evolutionarily conserved protein across species.[36] Most Wnt proteins figure in the region of 40 kDa, each possessing a characteristic 23 or 24 cysteine residues highly conserved in their spacing. This suggests that the formation of disulfide bonds plays a significant role in determining tertiary protein structure[37] Initiates Wnt signalling when it binds as a ligand to the Fz receptor with LRP[38] and destabilises the β-catenin degradation complex, dephosphorylating β-catenin and subsequently enabling its migration and accumulation in the cell nucleus for gene transcription [39]
  • The FRP family resembles the Wnt-interacting domain of Fz receptors, thus competitively sequesters Wnt from the Fz receptor[40].
  • WIF-1 has been shown to competitively antagonise Wnt binding to the Fz receptor [41]
  • Cerberus is a secreted protein that directly binds to the Wnt protein and inhibits signal transduction [42]
  • Dkk indirectly inhibits Wnt protein signalling by binding to the co-receptor LRP-6, thus making it unable to bind to Wnt for Fz signal transduction [43]
  • The extracellular sFRP family of proteins possess a consensus CRD sequence on their N-terminus, with which they directly bind to Wnt, and prevent its association with Fz receptors, thus antagonising the signal conduction [44]
  • Experiments suggest that axin indirectly blocks Wnt signalling, in a manner that renders further increases in Wnt levels ineffective [45]
Fz(FZD) 150px Fz houses a CRD on the N-terminus, seven transmembrane domains, and a PDZ domain on the C-terminus[37] Binds the Wnt ligand at the extracellular N-terminus for the initiation of the Wnt/β-catenin signalling pathway[37]
  • For inhibitors of the Fz receptor, refer to "Inhibitors" under Wnt
LRP-5/6 (LRP) 250px A protein that spans multiple domains. The extracellular component is comprised of four EGF-like repeats on the N-terminus[43] Co-receptor to the Wnt ligand in its interaction with the Fz receptor in signal transduction[46]. Causes translocation and association of axin to its intracellular tail, thus destabilising the β-catenin binding activity of axin[29]
  • Dkk antagonises LRP-5/6 binding to Wnt through competitive binding[43] and complexes with the transmembrane protein Kremen2 for intracellular removal cell through endocytosis[47]
Dsh (DVL) 250px A phosphoprotein [48] approximately 670 amino acids long [49]. Possesses a DIX domain, which is thought to facilitate interaction with Axin [50]. Prevents phosphorylatory activity of GSK-3β upon hyperphosphorylation by the Wnt/LRP-5/6 complex binding to the Fz receptor[51], thus preventing β-catenin ubiquitination and degradation, to promote translocation into the nucleus.
  • Nkd blocks feedback signalling, thus inhibiting Dsh[52]
  • Stbm binds to and jointly immunoprecipitates Dsh[53]
  • Dapper antagonises Dsh in complex with Axin, GSK-3β, CK-I and β-catenin, leading to degradation of β-catenin and subsequent reduced signalling[54]
  • PKC, a serine/threonine-specific protein kinase product of the non-canonical Wnt/Ca2+ pathway, inhibits Dsh through phosphorylation, preventing β-catenin nuclear translocation[55]
  • Experiments suggest that axin indirectly blocks Dsh function, in a manner that renders further increases in Dsh levels ineffective [45]
Axin (AXIN) 250px A 92 kDa protein [56]. Possesses a DIX domain, which is thought to facilitate interaction with Dsh [57]. In the absence of Wnt signalling, it constitutes the β-catenin ubiquitination complex along with APC and GSK-3β[38] and its role as a scaffolding protein enhances GSK-3β phosphorylation of β-catenin[58]
  • the antibiotic LMB prevents nuclear shuttling by blocking the NES- CRM1 interaction
  • Wnt downregulates axin through increased Dsh expression, hindering axin phosphorylation by GSK-3β, leading to decreased stability and ultimately a shorter half-life[59]
GSK-3β(GSK3β) 250px 46 kDa kinase [56]. Possesses a surface channel on the hydrophobic C-terminal helical domain that binds a 19 amino acid residue on Axin [60]. Constitutes the β-catenin ubiquitination complex along with axin and APC[38]; its primary role in the Wnt/β-catenin signalling pathway is inhibition of β-catenin nuclear translocation through phosphorylation of three amino acids at the N-terminus[61] after priming by CK-I[62], for subsequent ubiquitination and degradation by the proteasome. This activity is enhanced by GSK-3β phosphorylation of axin[58] and APC[63] which appears to promote phosphorylation of β-catenin by GSK-3β in the complex.
  • Frat1, which appears to be recruited by Dsh in complex, tightly binds GSK-3b even after complex dissociation and b-catenin degradation[64]
  • PKC inhibits GSK-3β phosphorylatory activity[65]
Diversin (ANKRD6) Diversin.JPG 776 amino acid with multiple ankyrin repeat domains [66]. Primes b-catenin for degradation by recruiting CK-I to phosphorylate serine 45 on the N-terminus before subsequent phosphorylation of threonine 41, serine 37 and serine 33 by GSK-3β and degradation by E3 ubiquitin ligase β-TrCP[62] There are no known inhibitors of Diversin in the published literature.
APC (APC) 150px A large 312 kDa protein [56]. Possesses a 25 amino acid SAMP repeat that is sufficient for full Axin binding [67] Possesses a numerous and varied set of roles ranging from cell migration and adhesion, cell cycle regulation and chromosome stability[68]. In the Wnt/β-catenin signalling pathway, APC constitutes the β-catenin ubiquitination complex along with axin and GSK-3β[38]. It binds to axin via SAMP elements[22], and to β-catenin via three 15-amino acid repeats and seven 20-amino acid repeats[69]
  • APC is itself an inhibitor of the β-catenin. For inhibitors of APC in the Wnt/β-catenin signalling pathway, refer to "Inhibitors" under Axin
β-catenin (CTNNB1) Murine bcat.jpg The N-terminus accommodates a critical sequence of thirteen armadillo repeats that competitively bind E-cadherin, LEF-1 and APC[70]. The C-terminus houses a glycine-rich transactivation domain[71] Involved in mediating both morphogenesis and maintenance of tissue integrity in the endothelium, bound to a-catenin that subsequently binds to the actin cytoskeleton. Gene expression is mediated in conjunction with TCF /LEF, upon translocation from the cytosol into the nucleus[70] The axin/APC/GSK-β complex phosphorylates b-catenin and marks it for ubiquitination and degradation by the proteasome[39]
TCF /LEF (TCF7/LEF) Protein structure LEF1 TCF4 TCF3.JPG The N-terminus constitutes the β-catenin interaction domain; TCF /LEF also possesses a HMG box DNA-binding domain[71] Mediates DNA binding when in complex with β-catenin; the N-terminus of TCF /LEF associates with the β-catenin C-terminus[71]
  • CAMKII, a serine/threonine-specific protein kinase product of the non-canonical Wnt/Ca2+ pathway, inhibits LEF downstream of β-catenin, acting at the transcription factor complex level[55]

Normal function: Roles of Wnt/β-catenin signalling

Embryonic development

Figure 4. Stem cell markers (red and green) in neural crest stem cells cultured with Wnt

The Wnt/β-catenin signaling pathway has been implicated as an important pathway in human fetal development. Through immunohistochemical staining, Eberhart and Argani (2001) localised nuclear beta catenin in fetal lung, placenta, kidney, cartilage, capillaries, adrenal glands and skin. This indicates that Wnt signaling regulates the development of specific set of organs and tissues.[72] For example, Wnt genes such as Wnt4 regulate the conversion of mesenchyme to epithelial cells in kidney morphogenesis.

In addition, Wnt/β-catenin signaling is also involved in maintaining the pluripotency of human embryonic stem cells (hESCs). Wnt3a promotes the reprogramming of somatic cells to pluripotency in conjunction with the classical transcription factors, Oct4, Sox2 and Nanog.[73] For example, Oct4 has the effect of repressing Wnt/β-catenin signaling in self renewing hESCs and is depressed during hESC differentiation[74]. Hence, this suggests that Wnt/β-catenin signaling is involved in differentiation rather than self renewal.

Adult tissue self renewal

Figure 5. Crypt villous junction, indicating the location of the progenitor compartment

Wnt/β-catenin signalling features in a great variety of processes during embryogenesis however the interesting concept to note about Wnt/β-catenin signalling is that it is heavily involved in adult tissue self renewal as well [1]. For example, in the gut, Wnt signaling is essential for the establishment of the progenitor compartment in an intestinal crypt [1]. This is further supported by Kuhnert et al (2004) who noted that the inhibition of Wnt signling results in the loss of crypts[75]. This means Wnt provides the mitotic stimulus for the progenitor cells in the crypts to proliferate.

Wnt/β-catenin signalling is also involved in the self renewal of bone tissue where several mouse models established the importance of Wnt signaling in bone homeostasis[1]. For instance, Babij et al (2003) observed how mice with gain of function mutations in ’’’LRP’’’5 (in osteoblasts) results in increased bone density and osteoclast activation[76]. In contrast, Kato et al (2002) noted how a loss of function in ’’’LRP’’’5 lead to decreased bone mass and faulty osteoblast maturation[77]. Hence, Wnt signalling plays an essential role in maintaining the maturation and proliferation of osteoblasts.

Other tissues involved in self renewal via Wnt signaling include hair follices and the haematopoietic system[1].


Muller et al (2002) investigated how Wnt/beta catenin signalling is involved in the stimulation of epithelial cell motility[78]. They discovered that when β-catenin was activated, it had the ability to induce epithelial migration in cell culture. Furthermore, the addition of growth factors enhanced the transcriptional activity of β-catenin and induced more migration than beta catenin alone[79]. This indicates evidence of synergism between Wnt signalling pathways and growth factors, which is particularly relevant in cancers. As a result, the cooperation between Wnt signaling and growth factors are likely stimulators of tumour progression and possibly the capacity to migrate and metastasise[79].

Normal function: Mechanism of action

  • β-catenin commonly exists as a subunit making up the cadherin protein complex, where it links E-cadherin to α-catenin [80]
  • Cadherin proteins play an integral role in the formation of adhesion junctions between cells [80]
  • β-catenin also acts to help anchor the actin cytoskeleton within the cell [80]
  • The β-catenin gene can be said to function as an oncogene given that the promotion of transcription of Wnt target genes by β-catenin has been shown to be involved in the development of an array of cancers including basal cell carcinoma, colorectal cancer and breast cancer.[81][82][83]

Figure 3. "Off" and "On" States of the Wnt/Beta-catenin Signalling Pathway

In the absence of Wnt (“off state”)

  • No extracellular "Wnt signal"
  • β-catenin targeted for proteosomal degradation by its incorporation into a “destruction complex” comprising:
  • APC and axin assemble into a structural scaffold, allowing the phosphorylation of the N-terminal of β-catenin by the coordinated action of CK1 and GSK-3β[85]
  • β-catenin is recognised by E3 ligase β-Trcp, ubiquinated and subsequently degraded by the 26S proteosome [86][38]
  • Level of β-catenin in the cytosol is low, and therefore does not reach the nucleus at a level sufficient enough to affect transcription
  • No transcription of Wnt target genes

In the presence of Wnt (“on state”)

  • Extracellular “Wnt signal” binds to a cell surface G-protein coupled receptor of the “Frizzled” (’’’FZ’’’) family
  • Low-density lipoprotein receptor-related protein (LRP) family functions as a transmembrane co-receptor for ’’’FZ’’’
    • Recruitment of axin to the membrane where it is degraded upon initiation of the Wnt signalling cascade
    • Dissociation of β-catenin into the cytoplasm without degradation by the “destruction complex" [89][38]
  • Activation (phosphorylation and poly-ubiquination) of proteins of the “Dishevelled” (Dsh) family
    • Implicated in the inactivation of the “destruction complex” by the recruitment of axin and GSK-3β away from the complex [90]
  • With the complex now interrupted, β-catenin resists ubiquination and reaches the nucleus in increased levels where it functions as a transcriptional enhancer alongside TCF[84]
  • β-catenin directly competes with Groucho/TLEs for TCF binding [91]
  • TCF promotes binding of RNA polymerase to DNA template strand
  • Induction of the downstream transcription of Wnt target genes, for example:
    • oncogenes such as c-Myc and cyclin D1 involved in cell cycle control [92]
    • MMP-7 and uPA, associated with metastasis and the invasion of cancer cells [82]

ANIMATION: Wnt signaling - on and off states

Tumour Cells

  • In a tumour cell, the Wnt siganalling pathway is activated abberantly either:
    • Innappropriately by an extracellular Wnt signal
    • In the absence of an extracellular Wnt signal
      • Usually results from a mutation in one of the subunits that comprise the “destruction complex”, resulting in an inability to degrade cytosolic β-catenin [92]
      • Mutant APC proteins characteristic of those associated with cancer, have been shown to upregulate transcription of Wnt target genes due to an inability to regulate levels of cytosolic and nuclear β-catenin [14]

MOVIE: A detailed explanation of Wnt/β-catenin signalling

Abnormal Function: Diseases associated with Wnt/β-catenin signalling

As described above, the Wnt/β-catenin signalling pathway plays a critical role in development, stem cell regulation and cellular processes such as proliferation and migration. Thus mutations in components of this pathway have been associated with cancers, hereditary disorders, developmental defects and other diseases.

For a comprehensive list of the range of diseases caused by mutations in Wnt-β-catenin components, please refer to Table 1 in Bryan T MacDonald, Keiko Tamai, Xi He Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell: 2009, 17(1);9-26[84]

Wnt/β-catenin Pathway and the Onset of Cancer

The high number of repressor genes involved in the Wnt/β-catenin pathway indicates that it is imperative for this pathway to be tightly regulated. [93] These repressor genes include APC, Axin 1 and Axin 2. Given the pathways involvements in the regulation of stem cell choice to proliferate or self renew, there is a strong correlation between mutations in these genes and the onset of cancer. The table below describes in further detail some mutations of the Wnt signalling pathway and associated cancers.

Mutations of the Wnt signalling pathway and associated cancers

Figure 5. The colon of a patient with Familial Adenomatous Polyposis (FAP)
Gene Normal function Mutation Effects of mutation Associated cancers [39]
β-catenin Primary Wnt effector. In the nucleus, β-catenin functions as a cofactor for TCF transcription factors which specify a subset of genes, which are responsible for determining cell fate and regulation of proliferation. [39] GOF mutation Any mutations that inhibit its destruction motif would cause constitutively active β-catenin signalling, leading to excessive stem cell renewal and proliferation thus predisposing the cells to the formation of tumours. [93]
  • Colorectal cancer
  • Prostate cancer
  • Uterine endometrial cancer
  • Melanoma
  • Hepatoblastoma (liver cancer)
  • Medulloblastoma (brain cancer)
  • Pancreatoblastoma (pancreatic cancer)
  • Ovarian carcinoma
  • Thyroid carcinoma
  • Pancreatic carcinoma
  • Hepatocellular carcinoma
  • Lung adenocarcinomas
  • Esophageal adenocarcinomas
  • Synovial sarcoma
APC Facilitates β-catenin degradation; acts as a tumour suppressor LOF mutation Mutational inactivation of APC inhibits the degradation of β-catenin, leading to the over-stabilisation and accumulation of β-catenin in the nucleus of the cell. [94] (See β-catenin above).

Colorectal Cancer (CRC)

  • LOF APC mutations in intestinal epithelial cells lead to constitutive β-catenin/Tcf4 complex activation, causing unrestrained production of crypt stem cells, resulting in cancer. [95] Once the cancer has spread widely through the body, it is often incurable and management focuses on chemotherapy and improving quality of life.
  • Activating mutations in the canonical Wnt pathway is responsible for approximately 90% of all colorectal cancer cases. [84] Of these, 85% are caused by loss of function mutations in APC. [39]
  • Colorectal cancer is the fourth most commonly diagnosed cancer in the world.

  • Colorectal cancer
  • Prostate cancer
  • Melanoma
  • Hepatoblastoma
  • Medulloblastoma
  • Ovarian carcinoma
  • Pancreatic non-ductal acinar cell carcinomas
  • Synovial carcinoma
  • Desmoid tumor
  • Gastric adenoma
  • Breast fibromatoses
  • Familial Adenomatous Polyposis (FAP) [Figure 4]
Axin 1 & Axin 2 Serve as scaffolding components for the β-catenin degradation complex. Acts as a tumour suppressor. LOF mutation Mutational inactivation of Axin 1 or Axin 2 inhibits the degradation of β-catenin, leading to the over-stabilisation and accumulation of β-catenin in the nucleus of the cell. (See β-catenin above).
  • Ovarian carcinoma
  • Hepatocellular carcinoma
  • Medulloblastoma
  • Predisposition to colon cancer [96]

Current research

Current Research on Inhibitors to Treat or Prevent Proliferation of Cancer

There is a large focus on finding more effective means of treating and preventing cancer. Current researchers are looking at inhibiting various components of the Wnt/β-catenin pathway to prevent the proliferation of cancer. Such treatments include:

  1. Small molecule inhibitors can be used to block the interaction between β-catenin and TCF, thus preventing constitutive transcriptional activities that lead to the proliferation of cancer. [84]
  2. Non-steroidal anti-inflammatory drugs (NSAIDs) function by interfering with β-catenin/TFC-dependent transcription, and have proven promising for the treatment and prevention of colorectal cancers. [84] Examples of NSAIDs include exisulind, sulindac and aspirin.[94] The use of NSAIDs was proven effective with a "40-50% reduction in mortality due to CRC in individuals taking NSAIDs".[84] Furthermore, studies are being conducted into the use of NSAIDs to inhibit cyclooxygenase-2 (COX-2) as an effective method of treatment and prevention of cancers. [84]
  3. Frizzled-related proteins can be used as natural antagonists to manage the Wnt pathway.
  4. A “recombinant adenovirus (Ad-CBR) that constitutively expresses the β-catenin binding domain of APC” [97] was developed, enabling APC to maintain its function of β-catenin degradation.
  5. Monoclonal antibodies are being used against Wnt proteins by inducing apoptosis in cancer cells [97].

Other Areas of Current Research

Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling[98]

De Lau et al (2011) demonstrated that the stem cell markers Lgr5 and Lgr4 are often co-expressed in Wnt-driven cellular proliferation, where they associate with the ’’’FZ’’’/’’’LRP’’’ Wnt receptor complex. This is of particular importance as the deletion of both the Lgr5 and Lgr4 genes results in decreased proliferation of cells in Wnt-driven compartments (e.g. intestinal crypts in a mouse model), a result similar to the mechanism of the Wnt signalling pathway in its “OFF” state.

Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling

Figure 6: Western blot results A. This panel confirms that the absence of protein in knockout cells B. ’’’LRP’’’5 response is weaker despite having two alleles in the absence of ’’’LRP’’’6, indicating how the majority of signal transduction is mediated through ’’’LRP’’’6

Dissecting Molecular Differences between Wnt Coreceptors ’’’LRP’’’5 and ’’’LRP’’’6[99]

The current understanding of the Wnt signalling pathway is that the ’’’LRP’’’5/6 co-receptor plays a critical role in the transduction of signals concerning processes such as skeletal remodelling, osteoporosis pathogenesis and cancer formation. MacDonald et al (2011), expand on the canonical understanding of the pathway by differentiating between the ’’’LRP’’’5 and ’’’LRP’’’6 co-receptors and the individual processes they are responsible for. By investigating the molecular basis for these differences, it has been demonstrated that the ’’’LRP’’’6 coreceptor plays a predominant role in embryogenesis and also exhibits a stronger signalling activity in vivo than the ’’’LRP’’’5 isotype (as depicted in Figure 6).

Dissecting Molecular Differences between Wnt Coreceptors LRP5 and LRP6

Identification of a novel inhibitor of the canonical Wnt pathway[100]

Because of the vital role Wnt signalling plays in processes such as inflammation, angiogenesis and fibrosis; the identification of a novel inhibitor of the pathway could provide a viable therapeutic intervention for diseases characterised by excessive activation of these processes. One such inhibitor showing promise is pigment epithelium-derived factor (’’’PEDF’’’), which has been demonstrated to attenuate Wnt signalling induced by conditions such as retinal ischaemia. This is believed to be a result of a physical interaction between ’’’PEDF’’’ and the ’’’LRP’’’6 co-receptor, which blocks initiation of the pathway by preventing activation of the ’’’FZ’’’ receptor.

Identification of a Novel Inhibitor of the Canonical Wnt Pathway

Inhibition of GSK3 by Wnt signalling - two contrasting models[101]

We have discussed the role of GSK-3β in the phosphorylation of β-catenin and subsequent ubiquitylation and proteosomal degradation of the protein (“off” state), although the mechanism by which Wnt activation inhibits these events (“on state”) is unclear. This is an important step because by blocking the phosphorylation of β-catenin, the protein is able to accumulate in the cytoplasm and carry out its biological function by promoting the transcription of Wnt target genes. Metcalfe and Bienz (2011) investigated two models proposing contrasting mechanisms by which GSK-3β is inhibited by Wnt activation. The first model proposed that Wnt induces the phosphorylation of ’’’LRP’’’6, which consequently inhibits the catalytic activity of GSK-3β, thereby preventing phosphorylation of β-catenin. The second model suggested that Wnt signalling induces the uptake of GSK-3β in vesicles called multivesicular bodies (’’’MVB’’’s), and therefore prevents any interaction between the enzyme and its substrate, β-catenin. The study also tested whether either of the models have any inclination to predominate in an acute vs. chronic setting of Wnt signalling.

Inhibition of GSK3 by Wnt signalling – two contrasting models

Future directions

The Role of Canonical WNT Signaling Pathway in Oral Carcinogenesis: A Comprehensive Review. [102]

This review article highlights the importance of the Wnt/β-catenin pathway to the pathogenesis of oral carcinogenesis. What is still poorly understood in the quest for a cure is the role, if any, of Wnt/β-catenin signalling in apoptosis, a crucial mode of combatting abnormal cell proliferation. Although much has been established in the mechanism of action of the canonical pathway, this topic of research is also relevant to developing treatments for many other diseases that are impacted by abnormalities in the apoptotic function of cells, and hence the continued interest in such research.

The Role of Canonical WNT Signaling Pathway in Oral Carcinogenesis: A Comprehensive Review

Dermal β-catenin activity in response to epidermal Wnt ligands is required for fibroblast proliferation and hair follicle initiation. [103]

Chen et al. have demonstrated the necessity of secreted Wnt ligands in not only fibroblast precursors, but also for the proliferation of fibroblasts, leading to thickening of the dermis, as well as hair follicles. However, the mechanism of the involvement of the secreted Wnt ligands in dermal fbroblast proliferation is yet to be defined, still resting on the determination of which broadly expressed Wnt ligands are required for dermal β-catenin activity, as well as what role (if any) dermal cell density plays in hair follicle formation. Elucidating such interactions pose implications for addressing diseases such as congenital human focal dermal hypoplasia and skin fibrosis.

Dermal β-catenin activity in response to epidermal Wnt ligands is required for fibroblast proliferation and hair follicle initiation


List of Abbreviations Used

  • APC: adenomatous polyposis coli
  • CAMKII: Ca2+/calmodulin-dependent protein kinase II
  • CK-I: casein kinase I
  • CRD: cysteine rich domain
  • CRM1: exportin-1 protein
  • DIX: dishevelled and axin domain
  • Dsh: Dishevelled
  • Fz: Frizzled
  • GSK-3β: glycogen synthase kinase-3β
  • HMG: high mobility group
  • LEF: lymphoid enhancer-binding factor
  • LMB: leptomycin B
  • LRP: lipoprotein receptor–related protein
  • NES: leucine-rich nuclear export signal protein
  • Nkd: naked cuticle
  • PKC: protein kinase C
  • SAMP: Ser-Ala-Met-Pro repeated amino acid segment
  • Stbm: strabismus
  • TCF: T cell factor
  • ‘’’NSAIDs:’’’ non-steroidal anti-inflammatory drugs
  • ‘’’MVB:’’’ multi-vesicular body
  • ‘’’PEDF:’’’ pigment epithelium-derived factor

List of Terminology

  • Agenesis: the inability to form an organ during embryogenesis due to the lack of primordial tissues
  • Agonist: a molecule which binds to a receptor to produce a physiological response
  • Antagonist: a molecule which inhibits the physiological function of another substance
  • Apoptosis: programmed cell death
  • C-terminus: the end of the polypeptide chain which features a free carboxyl group (-COOH)
  • Canonical: standard and well accepted
  • Caveolin: integral membrane proteins involved in receptor mediated endocytosis
  • Destruction motif: short sequences which provide stability of other proteins when deleted or mutated
  • Differentiation: the process by which cells become mature and specialised in structure and function
  • Disulfide bonds: a covalent bond between sulfur atoms
  • Gain of function mutation: mutation produces a protein which has an enhanced or abnormal function
  • Glycolipoprotein: a protein with attached lipid and carbohydrate groups
  • Homeotic gene: genes involved in embryonic development, specifically controlled the anterior-posterior axis
  • Histone deacetylation: the process by which histone deacetylase removes acetyl groups on the histones to increase affinity and condense DNA, thus preventing transcription
  • Homolog: gene which is related to another gene by common descent
  • Immunohistochemistry: detecting antigens on a tissue using labelled antibodies
  • Immunoprecipitation: the process of isolating a protein antigen using an antibody that binds to it to form an insoluble complex
  • Lethal mutation: a mutation which can result in the death of the organism
  • Ligand: a molecule which binds to another entity
  • Loss of function mutation: mutation produces a protein which has decreased or no function
  • Mnemonic: a tool which assists memory
  • Monoclonal antibody: an antibody engineered from a single clone of cells
  • Morphogenesis: the differentiation and growth of tissues and organs during embryo development
  • N-terminus: the start of the polypeptide chain which features a free amine group (-NH2)
  • Oncogene: genes which transform normal cells into cancerous cells
  • Pluripotency: the ability of stem cells to differentiate into ectoderm, mesoderm and endoderm
  • PDZ domain: a common structural domain of 80-90 amino acids of signalling proteins, whose name is derived from the first three letters of the first three proteins to be discovered to share the domain: post synaptic density protein, Drosophila disc large tumor suppressor, zonula occludens-1 protein
  • Proteasome: a large intracellular particle which degrades proteins
  • Repressor: a protein which binds to the operator and prevents transcription
  • Scaffolding protein: proteins which regulate signal transduction by organising and assembling signalling complexes
  • Self renewal: the capability to undergo numerous cell divisions and maintain undifferentiation
  • Sequester: to isolate or separate
  • siRNA: small interfering RNA which is involved in RNA interference
  • Tumour suppressor gene: produces proteins which control cell growth to prevent uncontrolled cell proliferation
  • Ubiquitylation: the process of adding ubiquitin

External links

Reference List

  1. 1.0 1.1 1.2 1.3 1.4 1.5 <pubmed>17081971</pubmed>
  2. Sharma RP Wingless, a new mutant in D.melanogaster. Drosoph. Inf. Serv: 1973, 50;134
  3. <pubmed>6297757</pubmed>
  4. <pubmed>3111720</pubmed>
  5. <pubmed>2499512</pubmed>
  6. 6.0 6.1 <pubmed>2225066</pubmed>
  7. <pubmed>1846319</pubmed>
  8. <pubmed>1962194</pubmed>
  9. <pubmed>1989880</pubmed>
  10. <pubmed>1335365</pubmed>
  11. <pubmed>8259518</pubmed>
  12. <pubmed>8259519</pubmed>
  13. <pubmed>7906389</pubmed>
  14. 14.0 14.1 <pubmed>7708772</pubmed>
  15. <pubmed>8757136</pubmed>
  16. <pubmed>8717036</pubmed>
  17. <pubmed>8985181</pubmed>
  18. <pubmed>8616874</pubmed>
  19. <pubmed>9298899</pubmed>
  20. <pubmed>9233789</pubmed>
  21. <pubmed>9118221</pubmed>
  22. 22.0 22.1 <pubmed>9554852</pubmed>
  23. <pubmed>9601644</pubmed>
  24. <pubmed>10517632</pubmed>
  25. <pubmed>9920888</pubmed>
  26. <pubmed>10092233</pubmed>
  27. <pubmed>11136974</pubmed>
  28. <pubmed>11029007</pubmed>
  29. 29.0 29.1 <pubmed>11336703</pubmed>
  30. <pubmed>12660735</pubmed>
  31. <pubmed>14600025</pubmed>
  32. <pubmed>16890161</pubmed>
  33. <pubmed>17549080</pubmed>
  34. <pubmed>19001663</pubmed>
  35. <pubmed>20412773</pubmed>
  36. <pubmed>9407023</pubmed>
  37. 37.0 37.1 37.2 <pubmed>11806834</pubmed>
  38. 38.0 38.1 38.2 38.3 38.4 38.5 <pubmed>9312064</pubmed>
  39. 39.0 39.1 39.2 39.3 39.4 <pubmed>12781368</pubmed>
  40. <pubmed>9118212</pubmed>
  41. <pubmed>10201374</pubmed>
  42. <pubmed>10067895</pubmed>
  43. 43.0 43.1 43.2 <pubmed>11357136</pubmed>
  44. <pubmed>9096311</pubmed>
  45. 45.0 45.1 <pubmed>9230313</pubmed>
  46. <pubmed>11029008</pubmed>
  47. <pubmed>12050670</pubmed>
  48. <pubmed>8288125</pubmed>
  49. <pubmed>8817329</pubmed>
  50. <pubmed>9920888</pubmed>
  51. <pubmed>7744250</pubmed>
  52. <pubmed>11752446</pubmed>
  53. <pubmed>12756182</pubmed>
  54. <pubmed>11970895</pubmed>
  55. 55.0 55.1 <pubmed>11472835</pubmed>
  56. 56.0 56.1 56.2 {{cite web | title = Entrez Protein: Axin1| url = http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein } Cite error: Invalid <ref> tag; name "Entrez" defined multiple times with different content Cite error: Invalid <ref> tag; name "Entrez" defined multiple times with different content
  57. <pubmed>9920888</pubmed>
  58. 58.0 58.1 <pubmed>9482734</pubmed>
  59. <pubmed>10196136</pubmed>
  60. <pubmed>12554650</pubmed>
  61. <pubmed>12027456</pubmed>
  62. 62.0 62.1 <pubmed>12000790</pubmed>
  63. <pubmed>8638126</pubmed>
  64. <pubmed>10428961</pubmed>
  65. <pubmed>8887544</pubmed>
  66. <pubmed>12454917</pubmed>
  67. <pubmed>10811618</pubmed>
  68. <pubmed>11978510</pubmed>
  69. <pubmed>10526234</pubmed>
  70. 70.0 70.1 <pubmed>10966653</pubmed>
  71. 71.0 71.1 71.2 <pubmed>9118222</pubmed>
  72. <pubmed>11441336</pubmed>
  73. <pubmed>18682236</pubmed>
  74. <pubmed>22392999</pubmed>
  75. <pubmed>14695885</pubmed>
  76. <pubmed>12817748</pubmed>
  77. <pubmed>11956231</pubmed>
  78. <pubmed>12372345</pubmed>
  79. 79.0 79.1 Cite error: Invalid <ref> tag; no text was provided for refs named PMID 12372345
  80. 80.0 80.1 80.2 <pubmed>7790378</pubmed>
  81. <pubmed>21173432</pubmed>
  82. 82.0 82.1 <pubmed>22550094</pubmed>
  83. <pubmed>18708403</pubmed>
  84. 84.0 84.1 84.2 84.3 84.4 84.5 84.6 84.7 <pubmed>19619488</pubmed>
  85. <pubmed>11955436</pubmed>
  86. <pubmed>15084453</pubmed>
  87. <pubmed>20676368</pubmed>
  88. <pubmed>10737769</pubmed>
  89. <pubmed>19279722</pubmed>
  90. <pubmed>17529994</pubmed>
  91. <pubmed>19460168</pubmed>
  92. 92.0 92.1 <pubmed>22466651</pubmed>
  93. 93.0 93.1 <pubmed>15054482</pubmed>
  94. 94.0 94.1 <pubmed>15372092</pubmed>
  95. <pubmed>22234609</pubmed>
  96. <pubmed>15042511</pubmed>
  97. 97.0 97.1 <pubmed>15578921</pubmed>
  98. <pubmed>21727895</pubmed>
  99. <pubmed>21887268</pubmed>
  100. <pubmed>21576363</pubmed>
  101. <pubmed>22083140</pubmed>
  102. <pubmed>22399606</pubmed>
  103. <pubmed>22434869 </pubmed>